down-arrowleft-arrowright-arrow

INDUSTRIES

Biotechnology

Overview

Haug Partners’ Biotech Litigation practice is comprised of trial lawyers, registered patent attorneys, and scientific advisors with advanced degrees in specialized technical fields, coupled with extensive experience in the biopharmaceutical industry. Our litigators draw on their legal and scientific expertise to explain complex legal and technical concepts to judges and juries.

Led by seasoned trial and appellate lawyer Ed Haug, the Haug Partners team has practiced litigation in the biopharmaceutical industry since the firm was founded in 1997. Our team includes attorneys who have served in a number of prominent leadership roles concerning developments in intellectual property cases and rules, including attorneys serving as a member of the District of New Jersey local rules committee; President of the Federal Circuit Bar Association; and Lead Administrative Patent Judge at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office. Unlike most of our competitor Biotech Litigation practices, Haug Partners has extensive experience working with both innovator and follow on drugs and is able to strategically counsel clients from both perspectives. Haug Partners’ unique cross-functional biopharmaceutical litigation, patent, and FDA practices also enable our Biotech Litigation team to provide seamless, interdisciplinary counseling and representation across all phases of a litigation lifecycle, from pre-suit strategy and patent analysis to Federal Circuit appeals. Haug Partners regularly appears before federal district courts and the Court of Appeals for the Federal Circuit. In recent years, the team has also made several appearances before the U.S. Supreme Court, including for a case that concerned the scope of the patent exhaustion doctrine in self-propagating technologies.

Industries

  • Artificial Intelligence
  • Automotive
  • Building Materials
  • Chemicals
  • Consumer Products
  • Education & Non-profit
  • Electronics
  • Financial Technology
  • Healthcare
  • Hospitality & Leisure
  • Internet of Things (IoT)
  • Life Sciences
  • Luxury, Fashion, & Beauty
  • Medical Devices
  • Mobile Tech & Telecommunications
  • Software Development & Platforms
  • Sports & Entertainment

Haug Partners LLP
+1.212.588.0800
haugpartners.com
©2020 Haug Partners

Biotechnology

Overview

Haug Partners’ Biotech Litigation practice is comprised of trial lawyers, registered patent attorneys, and scientific advisors with advanced degrees in specialized technical fields, coupled with extensive experience in the biopharmaceutical industry. Our litigators draw on their legal and scientific expertise to explain complex legal and technical concepts to judges and juries.

Led by seasoned trial and appellate lawyer Ed Haug, the Haug Partners team has practiced litigation in the biopharmaceutical industry since the firm was founded in 1997. Our team includes attorneys who have served in a number of prominent leadership roles concerning developments in intellectual property cases and rules, including attorneys serving as a member of the District of New Jersey local rules committee; President of the Federal Circuit Bar Association; and Lead Administrative Patent Judge at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office. Unlike most of our competitor Biotech Litigation practices, Haug Partners has extensive experience working with both innovator and follow on drugs and is able to strategically counsel clients from both perspectives. Haug Partners’ unique cross-functional biopharmaceutical litigation, patent, and FDA practices also enable our Biotech Litigation team to provide seamless, interdisciplinary counseling and representation across all phases of a litigation lifecycle, from pre-suit strategy and patent analysis to Federal Circuit appeals. Haug Partners regularly appears before federal district courts and the Court of Appeals for the Federal Circuit. In recent years, the team has also made several appearances before the U.S. Supreme Court, including for a case that concerned the scope of the patent exhaustion doctrine in self-propagating technologies.